ArticleJournal of cellular and molecular medicine2012
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.Current issues in molecular biology · 2023Review
- Use of Induced Pluripotent Stem Cells to Build Isogenic Systems and Investigate Type 1 Diabetes.Frontiers in endocrinology · 2021Article
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- Profiling changes in microRNAs of immature dendritic cells differentiated from human monocytes.Central-European journal of immunology · 2021Article
- Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020Review
- Ex vivo pulsed dendritic cell vaccination against cancer.Acta pharmacologica Sinica · 2020Review
- Dendritic cells pulsed with generated tumor cell lysate from Phyllanthus amarus Schum. & Thonn. induces anti-tumor immune response.BMC complementary and alternative medicine · 2018Article
- Dendritic Cell-Based Immunotherapy for Solid Tumors.Translational oncology · 2018Review
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities forFrontiers in immunology · 2018Review
- Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.Cancer immunology, immunotherapy : CII · 2017Article
- Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions.Oncology letters · 2017Article
- Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.Cancer immunology, immunotherapy : CII · 2017Article
- Article
- Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma.Oncotarget · 2015Article
- Optimizing dendritic cell-based approaches for cancer immunotherapy.The Yale journal of biology and medicine · 2014Review
- Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.Immunology · 2014Article
- Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.Cancer research · 2014Article
- MicroRNA profiling of activated and tolerogenic human dendritic cells.Mediators of inflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens. We were able to demonstrate extensive variability among different maturation strategies currently used in DC immunotherapeutic protocols that may at least partially explain limited clinical benefit of some clinical trials with such DC. We identified DC matured with interferon-γ and lipopolysaccharide as the most attractive candidate for future clinical trials in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.